Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Targeting EZH2 May Prevent Development of B-cell Lymphomas

By BiotechDaily International staff writers
Posted on 30 May 2013
Image: Senior author Dr. Ari Melnick (Photo courtesy of Weill Cornell Medical College).
Image: Senior author Dr. Ari Melnick (Photo courtesy of Weill Cornell Medical College).
A "master regulator" gene has been identified in immune system B-cell lymphocytes that when mutated fails to maintain the normal cell phenotype, which prompts the B-cells to enter a phase of uncontrolled cell division that results in the type of cancer known as B-cell lymphoma.

Most B-cell lymphomas arise from germinal center (GC) B-cells, since they divide rapidly while at the same time mutating their antibody genes. In some cases other genes become mutated as well, which can eventually result in lymphoma formation. GCs are sites within lymph nodes where mature B lymphocytes rapidly proliferate, differentiate, mutate their antibodies, and class switch their antibodies during a normal immune response to an infection. GCs are an important part of the B-cell humoral immune response, and they develop dynamically after the activation of B-cells by T-dependent antigen.

Investigators at Weill Cornell Medical College (New York, NY, USA) examined the role of the protein encoded by the EZH2 (enhancer of zeste homolog 2, also known as histone-lysine N-methyltransferase) gene, which is highly expressed in GC B-cells, in the process leading up to lymphoma formation.

They reported in the May 13, 2013, issue of the journal Cancer Cell that EZH2 repressed proliferation checkpoint genes and helped establish chromatin domains at key regulatory loci to transiently block the differentiation of B-cells away from the GC phenotype. Genomic deletion or pharmacologic suppression of EZH2 expression with a chemical inhibitor suppressed GC formation and function.

"EZH2 is a master regulator protein that turns off the brakes that prevent cell division, so it allows cells to divide without stopping," said senior author Dr. Ari Melnick, professor of medicine at Weill Cornell Medical College. "EZH2 prevents germinal cells from transitioning to antibody-secreting cells. Indeed, in the normal immune system EZH2 prevents B-cells from exiting germinal centers so that these cells can continue to undergo sustained rapid cell division, which continues until the immune system says to stop. Then EZH2 goes away, and B-cells can develop into antibody-secreting cells, which send antibodies into the circulation to fight off infection. Germinal center cells absolutely require EZH2 and the lymphomas that arise from germinal center cells inherit that need regardless of whether they have mutations."

"Researchers had thought EZH2 inhibitors would only help patients with a mutation in their EZH2 gene, which represents a small subset of lymphoma patients. What we found is that a majority of lymphomas turn out to be dependent on normal EZH2, not just mutated EZH2," said Dr. Melnick. "Our research indicates that these inhibitors will be remarkably effective. I am very optimistic."

Related Links:

Weill Cornell Medical College



RANDOX LABORATORIES
BIOSIGMA S.R.L.
SLAS - Society for Laboratory Automation and Screening
comments powered by Disqus

Channels

Drug Discovery

view channel

Omega 3 Found to Improve Behavior in Children with ADHD

Supplements of the fatty acids omega 3 and 6 can help children and adolescents who have a specific kind of have attention deficit hyperactivity disorder (ADHD). Moreover, these findings indicate that a customized cognitive training program can improve problem behavior in children with ADHD. Statistics show that 3%–6%... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Lab Technologies

view channel
Image: On target: When researchers introduced nanobodies they made to cells engineered to express a tagged version of a protein in skeletal fibers known as tubulin (red), the nanobodies latched on. The cells above have recently divided (Photo courtesy of Rockefeller University).

Turning Antibodies into Precisely Tuned Nanobodies

New technology has the potential to create nanobodies making them much more accessible than antibodies for all sorts of research. Antibodies control the process of recognizing and zooming in on molecular... Read more

Business

view channel

Two Industry Partnerships Initiated to Fuel Neuroscience Research

Faster, more complex neural research is now attainable by combining technology from two research companies. Blackrock Microsystems, LLC (Salt Lake City, UT, USA), a developer of neuroscience research equipment, announced partnerships with two neuroscience research firms—PhenoSys, GmbH (Berlin, Germany) and NAN Instruments, Ltd.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.